These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 8571322)

  • 21. Determinants of substrate specificity for factor XIII.
    McDonagh J; Fukue H
    Semin Thromb Hemost; 1996; 22(5):369-76. PubMed ID: 8989819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin.
    Schwartz ML; Pizzo SV; Hill RL; McKee PA
    J Clin Invest; 1971 Jul; 50(7):1506-13. PubMed ID: 5090065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
    Raut S; Gaffney PJ
    Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
    Glover CJ; McIntire LV; Brown CH; Natelson EA
    J Lab Clin Med; 1975 Oct; 86(4):644-56. PubMed ID: 1176815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A neoantigenic determinant in coiled coil region of human fibrin beta-chain.
    Lugovskoy EV; Gritsenko PG; Kolesnikova IN; Lugovskaya NE; Komisarenko SV
    Thromb Res; 2009 Mar; 123(5):765-70. PubMed ID: 18977516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. gamma-dimerization, alpha-polymerization, and plasmin degradation of human fibrin. Effect of various inhibitors of factor XIII on the patterns in SDS-electrophoresis and crossed immunoelectrophoresis.
    Feddersen JC; Gormsen J
    Thromb Haemost; 1976 Aug; 36(1):27-36. PubMed ID: 137555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains.
    Siebenlist KR; Meh DA; Mosesson MW
    Biochemistry; 1996 Aug; 35(32):10448-53. PubMed ID: 8756701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bleeding disorder with abnormal wound healing, acid-soluble clots and normal factor XIII.
    Ragaz S; Kemp G; Furlan M; Beck EA
    Thromb Haemost; 1976 Dec; 36(3):537-41. PubMed ID: 1037151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early alpha chain crosslinking in human fibrin preparations.
    Sobel JH; Thibodeau CA; Canfield RE
    Thromb Haemost; 1988 Oct; 60(2):153-9. PubMed ID: 3217916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
    Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
    Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clotting of mammalian fibrinogens by papain: a re-examination.
    Doolittle RF
    Biochemistry; 2014 Oct; 53(42):6687-94. PubMed ID: 25283163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ; Minkema J; Bouma BN; Jansen JW
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A microtiter plate assay for factor XIII A-chain-fibrin interactions.
    Achyuthan KE; Santiago MA; Greenberg CS
    Anal Biochem; 1994 May; 219(1):43-8. PubMed ID: 8059954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Availability of the B beta(15-21) epitope on cross-linked human fibrin and its plasmic degradation products.
    Chen F; Haber E; Matsueda GR
    Thromb Haemost; 1992 Mar; 67(3):335-40. PubMed ID: 1379385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA.
    Fukue H; Anderson K; McPhedran P; Clyne L; McDonagh J
    Blood; 1992 Jan; 79(1):65-74. PubMed ID: 1370210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen.
    Matsuka YV; Medved LV; Migliorini MM; Ingham KC
    Biochemistry; 1996 May; 35(18):5810-6. PubMed ID: 8639541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.